269 related articles for article (PubMed ID: 24959717)
1. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors.
Fang Z; Simard JR; Plenker D; Nguyen HD; Phan T; Wolle P; Baumeister S; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):279-88. PubMed ID: 24959717
[TBL] [Abstract][Full Text] [Related]
2. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening.
Yilmaz OG; Olmez EO; Ulgen KO
Comput Biol Chem; 2014 Feb; 48():1-13. PubMed ID: 24291487
[TBL] [Abstract][Full Text] [Related]
4. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.
Wang P; Zhang L; Hao Q; Zhao G
Mini Rev Med Chem; 2011 Nov; 11(13):1093-107. PubMed ID: 22353219
[TBL] [Abstract][Full Text] [Related]
5. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations.
Simard JR; Rauh D
Methods Enzymol; 2014; 548():147-71. PubMed ID: 25399645
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
7. Covalent-Allosteric Kinase Inhibitors.
Weisner J; Gontla R; van der Westhuizen L; Oeck S; Ketzer J; Janning P; Richters A; Mühlenberg T; Fang Z; Taher A; Jendrossek V; Pelly SC; Bauer S; van Otterlo WA; Rauh D
Angew Chem Int Ed Engl; 2015 Aug; 54(35):10313-6. PubMed ID: 26110718
[TBL] [Abstract][Full Text] [Related]
8. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
9. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
Verkhivker GM
Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
12. Insight into the structural mechanism for PKBα allosteric inhibition by molecular dynamics simulations and free energy calculations.
Chen SF; Cao Y; Han S; Chen JZ
J Mol Graph Model; 2014 Mar; 48():36-46. PubMed ID: 24374242
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors.
Siu T; Liang J; Arruda J; Li Y; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
Bioorg Med Chem Lett; 2008 Jul; 18(14):4186-90. PubMed ID: 18539456
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N
Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696
[TBL] [Abstract][Full Text] [Related]
15. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition.
Calleja V; Laguerre M; Parker PJ; Larijani B
PLoS Biol; 2009 Jan; 7(1):e17. PubMed ID: 19166270
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Yaroschak M; Bilodeau MT; Layton ME
Curr Top Med Chem; 2007; 7(14):1349-63. PubMed ID: 17692025
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Layton ME; Bilodeau MT
Curr Cancer Drug Targets; 2008 Feb; 8(1):7-18. PubMed ID: 18288939
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of novel allosteric FAK inhibitors.
Iwatani M; Iwata H; Okabe A; Skene RJ; Tomita N; Hayashi Y; Aramaki Y; Hosfield DJ; Hori A; Baba A; Miki H
Eur J Med Chem; 2013 Mar; 61():49-60. PubMed ID: 22819505
[TBL] [Abstract][Full Text] [Related]
19. Protocols for the Design of Kinase-focused Compound Libraries.
Jacoby E; Wroblowski B; Buyck C; Neefs JM; Meyer C; Cummings MD; van Vlijmen H
Mol Inform; 2018 May; 37(5):e1700119. PubMed ID: 29116686
[TBL] [Abstract][Full Text] [Related]
20. Detection of allosteric kinase inhibitors by displacement of active site probes.
Lebakken CS; Reichling LJ; Ellefson JM; Riddle SM
J Biomol Screen; 2012 Jul; 17(6):813-21. PubMed ID: 22453235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
